<SEC-DOCUMENT>0001493152-20-011653.txt : 20200623
<SEC-HEADER>0001493152-20-011653.hdr.sgml : 20200623
<ACCEPTANCE-DATETIME>20200623163500
ACCESSION NUMBER:		0001493152-20-011653
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20200617
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200623
DATE AS OF CHANGE:		20200623

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		20982591

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
DC 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 13 OR 15(d) OF THE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of report (Date of earliest event reported): June 17, 2020</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-15771</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>83-0221517</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
        or other jurisdiction</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
        incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
        Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
        Employer</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
        No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1330
Avenue of the Americas, 33rd Floor,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>(646)
813-4712</U></B><BR>
(Registrant&rsquo;s telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 22%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock, $0.01 par value</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABEO</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nasdaq
    Capital Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Appointment
of New Directors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 17, 2020, following the recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the
&ldquo;Board&rdquo;) of Abeona Therapeutics Inc. (the &ldquo;Company&rdquo;) appointed George Migausky and Paul Mann to serve
on the Board effective immediately. Messrs. Migausky and Mann will each serve as a Class 1 director whose term will expire at
the Company&rsquo;s annual meeting of stockholders to be held in 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Migausky has been appointed to serve as Chairman of the Audit Committee of the Board (the &ldquo;Audit Committee&rdquo;). Mr.
Mann has been appointed to serve as a member of the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board has determined that Messrs. Migausky and Mann each qualify as an &ldquo;independent director&rdquo; as defined under
Nasdaq Listing Rule 5605(a)(2), and meet the criteria for Audit Committee membership under Nasdaq Listing Rule 5605(c)(2).
Furthermore, the Board has determined that Mr. Migausky qualifies as an &ldquo;audit committee financial expert&rdquo; within
the meaning of Item 407(d) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
non-employee directors, Messrs. Migausky and Mann will each receive the same compensation as the other non-employee directors
of the Company under the standard arrangements and agreements described in the Company&rsquo;s 2020 Annual Meeting Proxy Statement.
The Company is not aware of any transaction or relationship involving Mr. Migausky or Mr. Mann requiring disclosure
under Item 404(a) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
previously reported, on April 21, 2020, the Company notified the Nasdaq Stock Market (&ldquo;Nasdaq&rdquo;) of noncompliance with
the independent director and audit committee requirements set forth in Listing Rules 5605(b)(1) and 5605(c)(2)(A). Also as previously
reported, the Company received a letter from Nasdaq on April 22, 2020 acknowledging the Company&rsquo;s noncompliance. On June
19, 2020, the Company received a letter from Nasdaq indicating that, based on the appointment of Messrs. Migausky and Mann to
the Board and the Audit Committee, the Company had regained compliance with the foregoing Listing Rules and that the matter is
now closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Employment
Agreement with Edward Carr</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 18, 2020, the Company and Edward Carr, the Company&rsquo;s Chief Accounting Officer, entered into a new letter agreement
regarding the terms of Mr. Carr&rsquo;s employment (the &ldquo;Agreement&rdquo;). Pursuant to the terms of the Agreement, Mr.
Carr will receive an annual base salary of $300,000 and is eligible for an annual bonus with a target bonus of 35% of his annual
base salary. Mr. Carr will be permitted to participate in all employee benefit plans that the Company may establish for similarly
situated employees, if and to the extent he is eligible pursuant to the terms of such plans and Company policies, which may be
modified by the Company at its discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Carr and the Company may each terminate his employment for any reason upon written notice to the other party. If the employment
is terminated for any reason, Mr. Carr will be entitled to (i) payment of any base salary earned but unpaid through the Termination
Date (as such term is defined in the Agreement); (ii) any accrued unused vacation days; (iii) additional vested benefits, if any,
in accordance with the applicable terms of applicable Company arrangements; and (iv) any unreimbursed expenses in accordance with
the Company&rsquo;s business expense reimbursement policies. In addition, if Mr. Carr&rsquo;s employment is terminated by the
Company other than for Cause or by Mr. Carr with Good Reason (as such terms are defined in the Agreement), Mr. Carr will be (i)
eligible to receive any annual bonuses awarded for a prior year but not yet paid or due to be paid as of the Termination Date,
and (ii) entitled to (A) a payment equal to the sum of six months of his base salary plus six months of his Target Annual Bonus
Opportunity (as defined in the Agreement), and (B) a payment equal to the premiums he would pay if he elected continued health
coverage under the Company&rsquo;s health plan for the six-month period following the Termination Date, less the applicable active
employee rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s obligations in the preceding sentence are conditioned upon, among other things, Mr. Carr&rsquo;s execution of
a release of claims in favor of the Company and its affiliates. The foregoing summary of the Agreement does not purport to be
complete and is subject to, and qualified in its entirety by, the full text of the Agreement filed as Exhibit 10.1 herewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
7.01 Regulation FD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has issued a press release, dated June 17, 2020, announcing the appointment of Messrs. Migausky and Mann to the Board.
The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein. The information furnished in Exhibit
99.1 hereto shall not be considered &ldquo;filed&rdquo; for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the liabilities of that section, nor shall it be incorporated
by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless
the Company expressly sets forth in such future filings that such information is to be considered &ldquo;filed&rdquo; or incorporated
by reference therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 0.65in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit No.</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex10-1.htm">Offer Letter between Abeona
    Therapeutics Inc. and Edward Carr, dated June 18, 2020</A></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press release, dated June
    17, 2020</A></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    23, 2020</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
    Therapeutics Inc.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brendan M. O&rsquo;Malley</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brendan
    M. O&rsquo;Malley</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate
    Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="margin-right: 0; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
10.1</FONT></P>

<P STYLE="margin-right: 0; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-1_001.jpg" ALT="Abeona LH logo.jpg" STYLE="height: 94px; width: 268px"></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">June
18, 2020</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">C/O
Edward Carr</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Edward,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
letter agreement sets forth the terms of your employment as VP, Chief Accounting Officer, effective June 16, 2020 (the &ldquo;<U>Effective
Date</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Duties; Best Efforts</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the VP, Chief Accounting Officer you shall continue to have the duties, responsibilities and authority commensurate therewith,
and shall continue to report to the Chief Executive Officer of the Company (the &ldquo;CEO&rdquo;). You shall perform all duties
and accept all responsibilities incident to such position as may be reasonably assigned to you. You represent you are not subject
to or a party to any employment agreement, noncompetition covenant, or other agreement that would be breached by, or prohibit
you from, executing this letter agreement (&ldquo;<U>Agreement</U>&rdquo;) and performing fully your duties and responsibilities
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
your employment, you will devote your best efforts and full time and attention to promote the business and affairs of the Company
and its affiliates, and shall be engaged in other business activities only to the extent that such activities do not materially
interfere or conflict with your obligations to the Company hereunder, including, without limitation, the obligations pursuant
to Section 4 below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<U>Compensation and Benefits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Base Salary</U>. As of the Effective Date, you will continue to receive a base salary of $300,000, as approved by the Compensation
Committee (the &ldquo;<U>Compensation Committee</U>&rdquo;) of the Board of Directors of the Company (the &ldquo;<U>Board</U>&rdquo;)
and payable in accordance with the regular payroll practices of the Company (&ldquo;<U>Base Salary</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Annual Bonus</U>. During your employment, you may be considered for an annual discretionary bonus (&ldquo;<U>Annual Bonus</U>&rdquo;)
in addition to your Base Salary, with a target of 35% of your Base Salary (&ldquo;<U>Target Annual Bonus Opportunity</U>&rdquo;).
Annual Bonus compensation in any year, if any, will be determined in the Company&rsquo;s sole discretion, and shall be based on
your performance and that of the Company, as well as market factors. Except as provided below under Section 3, to be eligible
to receive an Annual Bonus as described above, you must be employed in good standing, and not have provided notice of resignation
or been provided notice of termination, on the date that the Annual Bonus is paid.</FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-1_002.jpg" ALT="A screenshot of a cell phone&#10;&#10;Description automatically generated" STYLE="height: 56; width: 670"></FONT></P>

<P STYLE="margin-right: 0; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Equity Compensation. In connection with your employment, and subject to Compensation Committee discretion and approval, you will
be entitled to receive (i) stock option grants to purchase shares of Company common stock and (ii) other long-term equity compensation
grants (collectively, &ldquo;Equity Awards&rdquo;) under the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (&ldquo;Plan&rdquo;),
subject to the terms and conditions of the Plan and the agreement memorializing the terms of the Equity Awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
If you remain continuously employed from the Effective Date through the date of a Change in Control (as defined below), notwithstanding
the terms of any equity incentive plan or award agreements, as applicable, all outstanding unvested stock options granted to you
during your employment with the Company shall become fully vested and exercisable and will remain exercisable for three (3) months
following the date of a Change in Control, and all outstanding long-term equity compensation awards, other than stock options,
shall become fully vested and the restrictions thereon shall lapse. Pursuant to the terms of the Plan, the exercise price of the
stock options will be the fair market value of the Company&rsquo;s common stock on the date that the stock options were granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
Benefits. During your employment, you will be eligible to participate in such health and other group insurance and other employee
benefit plans and programs of the Company as are in effect from time to time, on the same basis as those in commensurate positions
of the Company. Your participation will be subject to the terms of the applicable plan documents and generally applicable Company
policies. The Company reserves the right to amend or terminate any employee benefit plan, program and policy in its discretion
at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
Paid Time Off. You will be entitled to twenty (20) days of paid time off (vacation days plus sick time/personal time) per year,
accrued at a rate in accordance with the Company&rsquo;s policies from time to time in effect, in addition to holidays observed
by the Company. Paid Time Off may be taken at such times and intervals as you shall determine, subject to the business needs of
the Company and the responsibilities of your position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<U>Employment Termination</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Termination of Employment; Accrued Amounts</U>. The Company may terminate your employment for any reason, and you may voluntarily
terminate your employment hereunder for any reason, in each case at any time upon written notice to the other party (the date
on which your employment terminates for any reason is herein referred to as the &ldquo;<U>Termination Date</U>&rdquo;). Upon the
termination of your employment for any reason, you (or your beneficiary or estate, as applicable, in the event of your death)
will be entitled to (i) payment of any Base Salary earned but unpaid through the Termination Date, (ii) any accrued unused vacation
days, (iii) additional vested benefits (if any) in accordance with the applicable terms of applicable Company arrangements, and
(iv) any unreimbursed expenses in accordance with the Company&rsquo;s business expense reimbursement policies (collectively, the
&ldquo;<U>Accrued Amounts</U>&rdquo;), <U>provided</U>, <U>however</U>, that if your employment hereunder is terminated (A) by
the Company without Cause (as defined below) or (B) by you for Good Reason (as defined below), then you will be eligible to receive
any Annual Bonus awarded for a prior year, but not yet paid or due to be paid as of the Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Severance</U>. If your employment is terminated (i) by the Company other than for Cause or (ii) by you for Good Reason (as
defined below), in addition to the Accrued Amounts and in lieu of any payments or benefits under any other Company separation
policy or program, you will be entitled to: (A) a payment equal to the sum of six (6) months of your Base Salary plus six (6)
of your Target Annual Bonus Opportunity (the amount of such payment, the &ldquo;<U>Severance Amount</U>&rdquo;); and (B) a payment
equal to the premiums that you would pay if you elected continued health coverage under the Company&rsquo;s health plan for you
and your eligible dependents for the six (6) month period following the Termination Date, less the applicable active employee
rate, which premiums will be calculated based on the rate determined under the COBRA rate in effect on the Termination Date (&ldquo;<U>Medical
Benefit Payment</U>&rdquo;); <U>provided that</U> any delays in the settlement or payment of such awards that are set forth in
the applicable award agreement and that are required under Section 409A of the Internal Revenue Code, as amended (the &ldquo;<U>Code</U>&rdquo;),
and the Treasury Regulations thereunder (&ldquo;<U>Section 409A</U>&rdquo;) shall remain in effect. The Company&rsquo;s obligations
to make the payments and provide the benefits set forth in (A) and (B) in this Section 3(b) shall be conditioned upon your continued
compliance with your obligations under Section 4 below and your execution and nonrevocation of a release of claims in favor of
the Company and its affiliates in a form provided by the Company (&ldquo;<U>Release</U>&rdquo;). Notwithstanding any provision
to the contrary herein (other than the provisions of Section 7 below), and without limitation of any remedies to which the Company
may be entitled, (I) the Severance Amount shall be paid in installments in accordance with the Company&rsquo;s regular payroll
practices during a six (6) month period commencing within sixty (60) days following the Termination Date (with the first such
payment to include all installment amounts from the Termination Date), and (II) the Medical Benefit Payment shall be paid in a
lump sum within sixty (60) days following the Termination Date; <U>provided that</U> the Release is effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Change in Control Termination</U>. Notwithstanding any other provision contained herein, if your employment hereunder is terminated
by you for Good Reason (as defined below) or by the Company without Cause, in each case within twelve (12) months following a
Change in Control, in addition to the Accrued Amounts and in lieu of any payments or benefits under any other Company separation
policy or program, you will be entitled to receive (A) a payment equal to the sum of nine (9) months of your Base Salary plus
nine (9) months of your Target Annual Bonus Opportunity (such amount, the &ldquo;<U>CIC Severance Amount</U>&rdquo;); and (B)
a payment equal to the premiums that you would pay if you elected continued health coverage under the Company&rsquo;s health plan
for you and your eligible dependents for the nine (9) months period following the Termination Date, less the applicable active
employee rate, which premiums will be calculated based on the rate determined under the COBRA rate in effect on the Termination
Date (&ldquo;CIC <U>Medical Benefit Payment</U>&rdquo;). If the Change in Control is a &ldquo;change in control event&rdquo; as
defined under Section 409A, (I) the CIC Severance Amount shall be paid in a lump sum within sixty (60) days following the Termination
Date; and (II) the CIC Medical Benefit Payment shall be paid in a lump sum within sixty (60) days following the Termination Date;
The Company&rsquo;s obligations to provide the payments and benefits described in this Section 3(c) shall be conditioned upon
your continued compliance with your obligations under Section 4 below and your execution and delivery to the Company of an effective
Release.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Resignation of Positions</U>. Upon your termination of employment with the Company for any reason, you will be deemed to have
resigned, as of the Termination Date, from all positions you then hold with the Company and its affiliates, and you agree to execute
all documents necessary to effectuate the same.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
<U>Cooperation</U>. Following the termination of your employment with the Company for any reason, you will reasonably cooperate
with the Company upon request of the CEO, General Counsel, or the Board, and be reasonably available to the Company (taking into
account your other business endeavors) with respect to matters arising out of your services to the Company and its subsidiaries,
including, in connection with any legal proceeding, providing testimony and affidavits; <U>provided</U>, <U>that</U>, the Company
shall make reasonable efforts to minimize disruption of your other activities. The Company shall reimburse you for reasonable
expenses incurred in connection with such cooperation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
<U>Definitions</U>. For purposes of this Agreement, the following terms have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
&ldquo;<U>Cause</U>&rdquo; shall mean: (A) your substantial failure to perform your duties (other than any such failure resulting
from incapacity due to physical or mental disability) that continues for fifteen (15) calendar days after written notice from
the Company; (B) your failure to comply with any valid and legal directive of the CEO or the Board (as applicable) that continues
for fifteen (15) calendar days after written notice from the Company; (C) your engagement in dishonesty, illegal conduct, or misconduct
(or the discovery of your having engaged in such conduct in the past), which, in each case, materially harms or is reasonably
likely to materially harm, reputationally, financially or otherwise, the Company or its subsidiaries; (D) your embezzlement, misappropriation,
or fraud, whether or not related to your employment with the Company; (E) your conviction of or plea of guilty or nolo contendere
to a crime that constitutes a felony; (F) your willful violation of a material policy of the Company; (G) your willful or grossly
negligent unauthorized disclosure of Confidential Information (as defined below); or (H) your material breach of any material
obligation under this Agreement or any other written agreement between you and the Company that continues for fifteen (15) calendar
days after written notice from the Company (if such breach is reasonably curable); or (I) any willful material failure by you
to comply with the Company&rsquo;s written policies or written rules, as they may be in effect from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
&ldquo;<U>Change in Control</U>&rdquo; shall have the meaning defined in subparagraph (ii) of the definition of such term under
the Appendix in the Plan as in effect on the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
&ldquo;<U>Good Reason</U>&rdquo; shall mean the occurrence of any of the following, in each case without your written consent:
(A) a material reduction of at least ten percent (10%) of your Base Salary other than a general reduction in Base Salary that
affects all similarly situated executives; (B) a material reduction of at least thirty percent (30%) of the Target Annual Bonus
Opportunity other than a general reduction in the Target Annual Bonus Opportunity that affects all similarly situated executives;
(C) a permanent and material relocation of your principal place of employment, which for purposes of this Agreement, means a relocation
of more than fifty (50) miles; (D) any material breach by the Company of any material provision of this Agreement; or (E) a material
adverse change in your title, authority, duties, or responsibilities (including the reporting structure applicable to you, other
than temporarily while you are physically or mentally incapacitated); <U>provided</U>, <U>however</U>, that you cannot terminate
your employment for Good Reason unless you have provided written notice to the Company of the existence of the circumstances providing
grounds for termination for Good Reason within sixty (60) calendar days following the initial existence of such grounds and the
Company has had thirty (30) calendar days from the date on which such notice is provided to cure such circumstances. If you do
not terminate your employment for Good Reason within sixty (60) calendar days after expiration of the cure period (in which the
Company shall not have so cured such grounds), then you will be deemed to have waived your right to terminate for Good Reason
with respect to such grounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<U>Restrictive Covenants</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer of employment is contingent on your signing the Company&rsquo;s Policy on Insider Trading, Whistle Blower Policy, Code of
Ethics, and the standard Employee Confidentiality, Non-competition and Proprietary Information Agreement attached hereto as <U>Exhibit
A</U>, the terms of which are incorporated herein by reference in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<U>At-Will Employment</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the Company is at-will. This means that you will have the right to terminate your employment relationship with
the Company at any time for any reason. Similarly, the Company will have the right to terminate its employment relationship with
you at any time for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<U>Section 409A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
To the extent applicable, it is intended that this Agreement (including all amendments hereto, if any) either meets the requirements
for exclusion from coverage under Section 409A, or alternatively complies with the requirements of Section 409A, so that the income
inclusion provisions of Section 409A(a)(1) of the Code do not apply to you. This Agreement shall be interpreted and administered
in a manner consistent with this intent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
To the extent that payment of amounts under this Agreement that are subject to Section 409A are payable upon termination of your
employment, such amounts shall only be payable if such termination also constitutes a &ldquo;separation from service,&rdquo; within
the meaning of Section 409A, from the Company and its affiliates. If you are deemed on the date of your separation from service
to be a &ldquo;specified employee&rdquo; (within the meaning of Section 409A(a)(2)(B) of the Code) of the Company, then, notwithstanding
any other provision herein, with regard to any payment that is &ldquo;nonqualified deferred compensation&rdquo; subject to Section
409A and that is payable on account of your &ldquo;separation from service,&rdquo; such payment shall not be made prior to six
(6) months from the date of your separation from service, following which all payments so delayed shall be paid to you in a lump
sum without interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Any taxable reimbursement of business or other expenses provided for under this Agreement that is subject to Section 409A shall
be subject to the following conditions: (i) the expenses eligible for reimbursement in one taxable year shall not affect the expenses
eligible for reimbursement in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than
the end of the year after the year in which such expense was incurred; and (iii) the right to reimbursement shall not be subject
to liquidation or exchange for another benefit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
In applying Section 409A to amounts paid pursuant to this Agreement, each payment shall be treated as a separate payment and any
right to a series of installment payments under this Agreement shall be treated as a right to a series of separate payments. Whenever
a payment under this Agreement specifies a payment period within a specified number of days, the actual date of payment within
the specified period shall be within the sole discretion of the Company. If the consideration and revocation period for the Release
spans two taxable years and any amount hereunder is &ldquo;nonqualified deferred compensation&rdquo; subject to Section 409A and
payable on account of your separation from service, such payment shall not be made or commence until the second taxable year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<U>Section 280G</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a change in ownership or control under Section 280G of the Code, if it shall be determined that any payment or distribution
in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) to or for your benefit, whether paid or payable
or distributed or distributable pursuant to the terms of this Agreement or otherwise (a &ldquo;<U>Payment</U>&rdquo;), would constitute
an &ldquo;excess parachute payment&rdquo; within the meaning of Section 280G of the Code, the aggregate present value of the Payments
under this Agreement shall be reduced (but not below zero) to the Reduced Amount (defined below) if and only if the Accounting
Firm (described below) determines that the reduction will provide you with a greater net after-tax benefit than would no reduction.
No reduction shall be made unless the reduction would provide you with a greater net after-tax benefit. The determinations under
this Section 8 shall be made as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The &ldquo;<U>Reduced Amount</U>&rdquo; shall be an amount expressed in present value which maximizes the aggregate present value
of Payments under this Agreement without causing any Payment under this Agreement to be subject to the Excise Tax (defined below),
determined in accordance with Section 280G(d)(4) of the Code. The term &ldquo;<U>Excise Tax</U>&rdquo; means the excise tax imposed
under Section 4999 of the Code, together with any interest or penalties imposed with respect to such excise tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
Payments under this Agreement shall be reduced on a nondiscretionary basis in such a way as to minimize the reduction in the economic
value deliverable to you. Where more than one payment has the same value for this purpose and they are payable at different times,
they will be reduced on a pro-rata basis. Only amounts payable under the Agreement shall be reduced pursuant to this Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
All determinations to be made under this Section shall be made by an independent certified public accounting firm selected by
the Company and agreed to by you immediately prior to the change in ownership or control transaction (the &ldquo;<U>Accounting
Firm</U>&rdquo;). The Accounting Firm shall provide its determinations and any supporting calculations both to the Company and
you within ten (10) days of the transaction. Any such determination by the Accounting Firm shall be binding upon the Company and
you. All of the fees and expenses of the Accounting Firm in performing the determinations referred to in this Section shall be
borne solely by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
All amounts paid to you under this Agreement during or following your employment shall be subject to withholding and other employment
taxes imposed by applicable law, and the Company shall withhold from any payments under this Agreement all federal, state and
local taxes that the Company is required to withhold pursuant to any law or governmental rule or regulation. You shall be solely
responsible for the payment of all taxes imposed on you relating to the payment or provision of any amounts or benefits hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
This Agreement may be executed by .pdf or facsimile signatures in any number of counterparts, each of which shall be deemed an
original, but all such counterparts shall together constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
From and after the Effective Date, this Agreement (including <U>Exhibit A</U> hereto) constitutes the entire agreement between
you and the Company, and supersedes all prior representations, agreements and understandings (including any prior course of dealings),
both written and oral, between you and the Company with respect to the subject matter hereof. In the event of any inconsistency
between this Agreement and any other plan, program, practice or agreement in which you are a participant or a party, this Agreement
shall control unless such other plan, program, practice or agreement is more favorable to you (term by term) or specifically refers
to this Agreement as not controlling.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
This Agreement and any of the provisions hereof may be amended, waived (either generally or in a particular instance and either
retroactively or prospectively), modified or supplemented, in whole or in part, only by written agreement signed by you and the
Company. This Agreement and your rights and obligations hereunder, may not be assigned by you, and any purported assignment by
you in violation hereof shall be null and void. The Company is authorized to assign this Agreement to a successor to substantially
all of its assets or business. Nothing in this Agreement shall confer upon any person not a party hereto, or the legal representatives
of such person, any rights or remedies of any nature or kind whatsoever under or by reason of this Agreement, except the personal
representative of the deceased. This Agreement shall inure to the benefit of, and be binding on, the successors and assigns of
each of the parties, including, without limitation, your heirs and the personal representatives of your estate and any successor
to all or substantially all of the business and/or assets of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
No remedy conferred upon a party by this Agreement is intended to be exclusive of any other remedy, and each and every such remedy
shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law
or in equity. Except as explicitly provided herein, no delay or omission by a party in exercising any right, remedy or power under
this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may
be exercised by such party from time to time and as often as may be deemed expedient or necessary by such party in its sole discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
This Agreement shall be construed and enforced in accordance with, and the laws of the State of New York, without giving effect
to the conflicts of law principles thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
Any reference to a Section of the Code shall be deemed to include any successor to such Section.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
This Agreement and the compensation payable hereunder shall be subject to any applicable clawback or recoupment policies, share
trading policies, and other policies that may be implemented by the Board from time to time with respect to officers of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Any notices required or permitted hereunder or necessary or convenient in connection herewith shall be in writing and shall be
deemed to have been given when hand delivered or mailed by registered or certified mail, if to the Company, to the CEO at the
address above, and if to you at the most recent address in the Company&rsquo;s records.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Please acknowledge your acceptance of this offer by returning a signed copy of this Agreement. If there are any other agreements
of any type that you are aware of that may impact or limit your ability to perform your job at the Company, please let us know
as soon as possible. In accepting this offer, you represent and warrant to the Company that you are not subject to any legal or
contractual restrictions that would in any way impair your ability to perform your duties and responsibilities to the Company,
and that all information you provided to the Company is accurate and complete in all respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-right: 0; page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt 0 0pt 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Jo&atilde;o Siffert, M.D.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Jo&atilde;o
    Siffert, M.D.</I></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief
    Executive Officer</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Abeona
    Therapeutics Inc.</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
accept this offer of employment with Abeona Therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature:</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Edward Carr</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    18, 2020</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.75pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="ex10-1_002.jpg" ALT="" STYLE="height: 56; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Options: Last -->
    <DIV STYLE="margin-right: 0; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 61px; width: 204px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abeona
Therapeutics Further Strengthens Board with Appointment of Two New Independent Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEW
YORK and CLEVELAND, Jun. 17, 2020 &ndash; Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell
therapy, today announced Board of Director appointments that strengthen and expand the Company&rsquo;s leadership. George Migausky
and Paul Mann were appointed as independent directors, effective June 17, 2020. In addition to their Board service, Mr. Migausky
will serve as Chairman of the Company&rsquo;s Audit Committee and Mr. Mann will serve as a member of the Audit Committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;George
and Paul are highly regarded professionals with substantial financial management, operational, business development and capital
raising experience in the biotechnology industry, bringing essential knowledge and expertise to Abeona,&rdquo; said Brian Pereira,
M.D., Executive Chairman of Abeona. &ldquo;The addition of George and Paul complements the skills and experiences of Abeona&rsquo;s
existing Board members and leadership team, and we are confident that they will provide valuable perspective and guidance as we
continue to advance our gene and cell therapies aimed at addressing urgent unmet needs.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Migausky brings more than 30 years of experience in senior financial management to Abeona&rsquo;s Board, having served as Chief
Financial Officer (CFO) of several public biopharmaceutical and clinical diagnostic companies. Most recently, Mr. Migausky served
as interim CFO of Ocular Therapeutix, Inc. and previously served as Executive Vice President and CFO of Dyax Corp. for eight years
through its acquisition by Shire plc for $6.4 billion. Mr. Migausky&rsquo;s previous roles include CFO of Wellstat Management
Company, as well as CFO at IGEN International and BioVeris Corporation through their respective acquisitions by F. Hoffman LaRoche,
and Manager, Emerging Business Services at Deloitte &amp; Touche. Mr. Migausky currently serves on the Board of Directors and
Chair of the Audit Committee at Immunovant, Inc., is an independent member of the Board of Directors at Hyperion Catalysis International,
and a trustee for the Massachusetts Eye and Ear Institute. He received his MBA from Babson College and his BS from Boston College.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Mann has over 20 years of experience in the financial and biotechnology industries. Most recently, he served as CFO at PolarityTE,
Inc., a biotechnology and regenerative biomaterials company, where he was responsible for all financial operations. Prior to that,
Mr. Mann was the Healthcare Portfolio Manager at Highbridge Capital Management and has held positions with Soros Fund Management,
UBS Investment Group, Morgan Stanley and Deutsche Bank. Mr. Mann began his career as a scientist at Procter and Gamble and is
named as an inventor on patents for skincare compounds and technologies. Mr. Mann has an MA (Cantab) and an MEng from Cambridge
University where he studied Natural Sciences and Chemical Engineering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Abeona Therapeutics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abeona
Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona&rsquo;s
clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in
Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS
IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company&rsquo;s portfolio of AAV-based gene therapies also features
ABO-202 and ABO-201 for CLN1 disease and CLN3 disease, respectively. Abeona&rsquo;s library of novel, next-generation AIM&trade;
capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona&rsquo;s fully functional,
gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL<SUP>TM</SUP> study and is capable
of clinical and commercial production of AAV gene therapies. For more information, visit <U>www.abeonatherapeutics.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B><I>This press release contains certain statements that are forward-looking within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks
and uncertainties. These statements include statements about the Company&rsquo;s clinical trials and its products and product
candidates, future regulatory interactions with regulatory authorities, as well as the Company&rsquo;s goals and objectives. We
have attempted to identify forward looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; and similar expressions (as well as other words or expressions referencing future
events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results
may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous
risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations,
and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials,
the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition,
the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve
or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks
associated with data analysis and reporting, and other risks as may be detailed from time to time in the Company&rsquo;s Annual
Reports on Form 10-K and quarterly reports on Form 10-Q and other periodic reports filed by the Company with the Securities and
Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect
events or circumstances occurring after the date of this presentation, whether as a result of new information, future developments
or otherwise, except as required by the federal securities laws.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Greg
Gin<BR>
VP, Investor Relations<BR>
Abeona Therapeutics<BR>
+1 (646) 813-4709</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ggin@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Media
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scott
Santiamo<BR>
Director, Corporate Communications<BR>
Abeona Therapeutics<BR>
+1 (718) 344-5843<BR>
<U>ssantiamo@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex10-1_001.jpg
<TEXT>
begin 644 ex10-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !> 0P# 2(  A$! Q$!_\0
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M*,?XL( ?UIRO=6'*]U8M75U'9VYFFSL! .!D\D ?J:?-,EO"\TK!8XU+,Q[
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$OL?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex10-1_002.jpg
<TEXT>
begin 644 ex10-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U GH# 2(  A$! Q$!_\0
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M63:OZ'^M?#_M?8?ZQ<.^VU7+]>C>ZW]WVVZZJ_SZGV)YB]R/J#G^@/Z4I?T
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M6_AQXQT_4M%UK0+[Q,=2TSQ7X?\ &5UH13PMI%I'<_$"SGE34_#(N$%E8:^
MOF\M/A;B&M_:/LLNE+ZE6IX>HU*G;#UJK4*<)N5>*DY3:2LY*[BM7)1>]7CC
MA*A_9_M<^:^M1<X7H/\ ?1BFW*2C0;@E9M\MK)-NR5U^KGF8*AA@GMGIZ9./
MS]/>F^:P#%DV@=/FSDGM]WCOSZC%?G-\3_\ @HOX,^%WB_X#>&=7^&OB[4(O
MCZOPZ;PU<6&O_#I->B/Q*ODLM/6P\!WWBVU\<>*#X8#BX\<GP]H=V=#@>-K
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MA7GB_28Q?Z%8Z_J6EW&JJZQZ.NJ B0\-7A/B^"4O]4N(K/VVV!JZ/#NU=/\
M<S<94O\ EY&2C.":;BTU?:EQYP9-V_UOX=E\.V,@K\^L+7J)-2^RU=.SU/L0
MW']U5/MO(_\ :9H%Q_>51[;R?_:8KXMC_P""B'[&<ECXOU+_ (7OX6@T_P "
M^'[[Q9XCU"]MO$%I80^%M,UK3O#VH>(]+O9M%2W\1:+;ZOJVGV9U#PZ^JP-)
M<QD-L)9;,G[?_P"R6/ NJ?$:/XM6-UX4T7QA>^ -5O+#P_XRO[VP\9Z=H_\
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M5D_WE2$HI:/2[5K7\^KQIP[0K+#5<;)5;RC9TY[P7-):0MHM7^A^H'GJN!(
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M./\ 5YMTY66:MV5*7-3;C-/1IVBFTGJTG]:_:&_N1_\ ?X?_ !%'VAO[D?\
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M:^*M24_\3'Q-=9(K[&_X7%X8_P"@%\3_ /PSGQ;_ /F'H_X7%X8_Z 7Q/_\
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M3D6TCM$3&WTW_A<7AC_H!?$__P ,Y\6__F'H_P"%Q>&/^@%\3_\ PSGQ;_\
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MB5XU\*>,H=8^(&J^)/'_ (GAMOB#K?Q$'Q.U[P3XI\4IXZE>^\,:M)=6NO\
MP[\'WGA*]\':]X,/A.WT2TL=-MV@4YW? G_!*_X):)\-OB/X-\>>(_&/C?Q7
M\5[;4;+Q=\1M-\0>*?#.K:?9:EKNG>([BQ\":5J?BWQE8>#K6\U72=/N/$OE
M2:E=_$4VR#XHWGC<%@?N;_A<7AC_ * 7Q/\ _#.?%O\ ^8>C_A<7AC_H!?$_
M_P ,Y\6__F'KO_UW\1OJ']F?V_F2P2G&I[&.-<7S1E"<5[6,HUO9QE3IM4O:
M>R7)"*I*,(0CYO\ Q#?P]_M+^U_]5\J_M"UO;_5W:VJ_@\_L+ZOWO9<W6]]3
MX?T7_@E-^SYX8T3PMI'A+QC\:/!MWX/UGXP:[I7B;P;X\M_"GBJ6^^.L'A*+
MXC/J&L:'HUDUR=2;P;I,]DZ0P/I\PD9#*$@$-^Q_X)2?LE:/X[\%>/M"T#Q%
MI5]X'T;P-H=CI$NM6WB/2-1M?AWIW]C^%[G4)_&6G^)/$=GJ-KI?^AWU[X;\
M0: ^M( VN+J3@EOM'_A<7AC_ * 7Q/\ _#.?%O\ ^8>C_A<7AC_H!?$__P ,
MY\6__F'KG_ULX^YI2_MS,U*;DYRCF$XRFYMRDYN,HRG>4I27-*2C*4Y04)3D
MY=$> >!(I)<-939))7PJE9)627-)VT2VM>RO>RM\6Q?\$JOV95\/:AX6N]3^
M+VJZ&G@R]^'G@BRU7XEZE<+\*/!6I:OI&MWV@?#F2&WMI;"UGO\ 0-%<2>(7
M\2W$<>FVT E,"F(]+\8?^":O[._QNU_QMXE\87OQ)M=2\?\ C3PWXZ\01Z#X
MVDL=+;5O#'PV/PGL[6RTB[L=1TZSTV[\&G[-J,,=O]JN[XF_:\5\(/JW_A<7
MAC_H!?$__P ,Y\6__F'H_P"%Q>&/^@%\3_\ PSGQ;_\ F'JUQCXB+%PQRXBS
MA8NG&I&GB%FE15*<:U2%6LH6M&'M:L(5:KC3BZE6*J3<JEYR;X!\/WAG@WPA
MPY]6;BW2_LC"<K<4XQ;?*YMQBW&+<GRQ;4;+0^0-5_X)B_L]:KX>A\)C6_BM
MIGAH? [X9_ "_P!'TGQPEG8ZYX)^$'B:7Q5\/KK6[$Z7+IMSXB\.ZA<W\%KJ
M]K8637-AJ^JVFIPZA'-9BPO?&;_@FA^SA\=/$7BKQ;XT3QDOB?Q3XW\+^/\
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M%XIMM3>;Q/JU_='5H+:QU_RYVC_M;(5A]U?\+B\,?] +XG_^&<^+?_S#T?\
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M9;N28L@B[_\ X7%X8_Z 7Q/_ /#.?%O_ .8>C_A<7AC_ * 7Q/\ _#.?%O\
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M7]EW7%U_X2V<1NM*>TBAL;R..+7L6A;7K-/LURT:8V_5W_"XO#'_ $ OB?\
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M:%YR:$YT]?M?_A<7AC_H!?$__P ,Y\6__F'H_P"%Q>&/^@%\3_\ PSGQ;_\
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MFDWS)IJ]ERK0O+^&.%LKQ'UO 9+EV'Q%N7VJPM.;M:UK554C:VGP_-GRE/\
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MIZ*.7^]/_P &3_S#V5/^5?C_ )D'DG^\/^^!_C1Y)_O#_O@?XU/11R_WI_\
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MZ?\ X,G_ )A[*G_*OQ_S(/)/]X?]\#_&CR3_ 'A_WP/\:GHHY?[T_P#P9/\
MS#V5/^5?C_F0>2?[P_[X'^-'DG^\/^^!_C4]%'+_ 'I_^#)_YA[*G_*OQ_S(
M/)/]X?\ ? _QH\D_WA_WP/\ &IZ*.7^]/_P9/_,/94_Y5^/^9!Y)_O#_ +X'
M^-'DG^\/^^!_C4]%'+_>G_X,G_F'LJ?\J_'_ #(/)/\ >'_? _QH\D_WA_WP
M/\:GHHY?[T__  9/_,/94_Y5^/\ F0>2?[P_[X'^-'DG^\/^^!_C4]%'+_>G
M_P"#)_YA[*G_ "K\?\R#R3_>'_? _P :/)/]X?\ ? _QJ>BCE_O3_P#!D_\
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MU6#_ -K_ (^L)I^_]G_GV]:?(R0V0<())6;8=P.9 Q;).&)E;,?./+X7&!T
M <UH7!#NCKO$BJ\(PCH1Y; JRL2H"J26RP&">3116;@GNY];+VD[*_9<VGR-
M-5&G%2FE2_AI3DN7YIWE_P!O-E9]-<O&R7"IB226;,&\RNZ>6-I,H6,+&749
M60G=DGC!E:Q#;3YI!BW>3Q(53='L^=?._> '#8)7/(/&,%%:N<W:\GHK+76S
M?5[OMK?W?=VT(=.DX4Z;HT>2EK3BJ4$HVQ'UO2R7_,0O:^<M[K0E^S-QF0?*
M^Y<+(/E_NO\ O_WG_ OEZ?)QR?91U)1BV/,RLN#Q@^6OGXBR><C<>QR<,"BH
ML_YIKTG)?J6G);3J?^#)>O<@:P=FBS/^[2,B2,(Z^;-\O[UF$_W<HI,1#*<8
MW8 P-I^Z1Y1(F^0Q%RT(8-Y(8(,>8N ,J< Y!0$$$\%%5S2_GGLU\<MFV^^N
MKZ]H_P JMG"E&$9PBZBC4=YIU:CN[89:-R;C_NF'TC97@WO.IS3/:%^/-(5@
MV[B0N'*[0T3F7]T ,_*%;.< @9S.(OEVDY'T_P#K^G'!]/2BBFYR=M=O)?Y?
MTM#6<G4CR3]Z/9I?Y7Z$M%%%2(**** "BBB@ HHHH **** "BBB@ HHHH **
A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  ] ,P# 2(  A$! Q$!_\0
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M)N]F$)/F<66Z***HU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM^5PZGW!'UI+W3GNI5DCN6B*KM*E%=3[X/?WIMII$=LLF^1I'D?>S !!G '
*''0"C6XO?YC_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
